Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial
Primary result · Failure to enter and sustain remission (relapse ≤12 months after ATD cessation, inability to stop ATD within 24 months, or RAI or thyroidectomy)Result — go to the resultRR for failure to enter and sustain remission 1.30 CI 0.95–1.78Authors' conclusion
Vitamin D supplementation did not improve the treatment of GD in patients with normal or insufficient vitamin D status.
Study context
- Population
- Adults with first-time diagnosis of Graves' disease (GD) treated with antithyroid drug (ATD); excluded pregnancy and glucocorticoid treatment; aged 44 ± 14 years, 79% female; inclusion 2015–20174 withdrew consent
- Participants
- 278 adults
- Comparison
- Vitamin D 70 mcg once daily (2800 IU) vs placebo, as add-on to ATD and for 12 months after ATD cessation
- Primary endpoint
- Failure to enter and sustain remission: relapse of hyperthyroidism within 12 months after ATD cessation, inability to stop ATD within 24 months, or radioiodine treatment or thyroidectomy
Methodological detailsmulticenter, double-blinded, placebo-controlled, Inclusion 2015–2017; study completion by December 2020
- Multicenter
- Double-blinded
- Placebo-controlled
- Inclusion 2015–2017; study completion by December 2020
Primary result
As reported in the abstract
Failure to enter and sustain remission (relapse ≤12 months after ATD cessation, inability to stop ATD within 24 months, or RAI or thyroidectomy)
RR for failure to enter and sustain remission
1.30
CI 0.95–1.78
By group
Vitamin Dvs Placebo
RR for failure to enter and sustain remission 1.30 (CI 0.95–1.78)
Safety
- No adverse effects were found
Original publication
Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial. Thyroid. Published 26 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →